- BNF:
- Immune System & Malignant Disease
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- None
Comments
RED:
- NICE TA439: cetuximab and panitumumab for previously untreated metastatic colorectal cancer. (Decision date - May 2017).
- NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. (Decision date - Oct 2017).
Do Not Prescribe (DNP):
- NICE TA242: Colorectal cancer (metastatic) 2nd line. Cetuximab – not recommended alone or in combination. (Decision date - Feb 2012).
NHS England commissioned - to be used in line with NHSE commissioning intentions.
This drug can be funded through the cancer drug fund - seek advice from oncologist/haematologist
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again